p53 protein expression in ductal carcinoma in situ (DCIS) of the breast

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Breast Cancer Research and Treatment

• Publication date

  1997-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1023/A:1005741723479PMID 9065612
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The classification of ductal carcinoma in situ and its association with biological markers.

  1994cited by this paper
• Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity.

  1994cited by this paper
• The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer.

  1994cited by this paper
• p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data.

  1994cited by this paper
• Overexpression of the p53 Tumor Suppressor Gene Product in Primary Lung Adenocarcinomas Is Associated with Cigarette Smoking

  1993cited by this paper
• Noninvasive ductal carcinoma of the breast: the relevance of histologic categorization.

  1993cited by this paper
• p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein.

  1993cited by this paper
• p53 Mutations and c‐erbB‐2 Amplification in Intraductal and Invasive Breast Carcinomas of High Histologic Grade

  1993cited by this paper
• Reproducibility of mitosis counting in 2,469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project.

  1992cited by this paper
• Ductal carcinoma in-situ of the breast; second EORTC consensus meeting.

  1992cited by this paper
• Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours.

  1992cited by this paper
• Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.

  1992cited by this paper
• Expression of mitoses per thousand cells and cell density in breast carcinomas: a proposal.

  1992cited by this paper
• p53 expression in neoplasms of the uterine corpus.

  1992cited by this paper
• The impact of mitotic index on predicting outcome in breast carcinoma: a comparison of different counting methods in patients with different lymph node status.

  1991cited by this paper
• Expression of p53 protein in infiltrating and in‐situ breast carcinomas

  1991cited by this paper
• Maintenance of p53 alterations throughout breast cancer progression.

  1991cited by this paper
• p53 alterations in all stages of breast cancer

  1991cited by this paper
• Identification of p53 gene mutations in bladder cancers and urine samples.

  1991cited by this paper
• Relation between p53 overexpression and established prognostic factors in breast cancer.

  1991cited by this paper
• Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas.

  1991cited by this paper
• Measuring cell proliferation.

  1991cited by this paper
• DNA analysis of ductal carcinoma In situ of the breast. A comparison with histologic features

  1991cited by this paper
• p53 expression in human breast cancer related to survival and prognostic factors: An immunohistochemical study

  1991cited by this paper
• Increased expression of mutant forms of p53 oncogene in primary lung cancer.

  1990cited by this paper
• Cancer. A deadly inheritance.

  1990cited by this paper
• A genetic model for colorectal tumorigenesis.

  1990cited by this paper
• Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro

  1990cited by this paper
• Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.

  1990cited by this paper
• Mitosis counting in tumors.

  1990cited by this paper
• p53: oncogene or anti-oncogene?

  1990cited by this paper
• Mutations in the p53 gene occur in diverse human tumour types

  1989cited by this paper
• Assignment of common allele loss in osteosarcoma to the subregion 17p13.

  1989cited by this paper
• Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life

  1988cited by this paper
• P53 expression in breast cancer

  1988cited by this paper
• A cancer family syndrome in twenty-four kindreds.

  1988cited by this paper
• Localization of gene for human p53 tumour antigen to band 17p13

  1986cited by this paper
• Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression.

  1986cited by this paper
• Role of the p53 protein in cell proliferation as studied by microinjection of monoclonal antibodies

  1984cited by this paper
• The cellular protein p53 in human tumours.

  1984cited by this paper
• Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation

  1984cited by this paper
• T antigen is bound to a host protein in SY40-transformed cells

  1979cited by this paper
• Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?

  1969cited by this paper
• Histological Grading and Prognosis in Breast Cancer

  1957cited by this paper

• Is loss of p53 a driver of ductal carcinoma in situ progression?

  2022cites this paper
• The Expression and Prognostic Value of p53 Gene in Invasive Ductal Carcinoma Breast: A Study in Mahatma Gandhi Memorial Medical College Indore M.P

  2019cites this paper
• The Expression and Prognostic Value of p 53 Gene in Invasive Ductal Carcinoma Breast : A Study in Mahatma Gandhi Memorial Medical College Indore

  2019cites this paper
• Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile

  2018cites this paper
• Intratumoral Heterogeneity in Ductal Carcinoma In Situ: Chaos and Consequence

  2018cites this paper
• Current Approaches to Diagnosis and Treatment of Ductal Carcinoma In Situ and Future Directions.

  2017cites this paper
• Prognostic value of COX‐2, P53, and EZH‐2 evaluated by quantitative image analysis in premalignant and malignant breast lesions

  2015cites this paper
• Molecular Markers in DCIS

  2015cites this paper
• Expression of p53, bcl-2, bax and bcl-xl in ductal carcinoma in situ (DCIS) of the breast

  2015cites this paper
• P53 Overexpression in Ductal Carcinoma in situ of the Breast

  2014cites this paper
• Utility of Immunohistochemical Markers in Irradiated Breast Tissue: An Analysis of the Role of Myoepithelial Markers, p53, and Ki-67

  2014cites this paper
• Immunohistochemical P 53 Expression in Breast Carcinoma with Correlation to Clinico-Pathological Parameters

  2013cites this paper
• Outcome of Ductal Carcinoma in Situ in Patients with or Without p53 Mutations

  2012cites this paper
• Intraductal Proliferative Lesions of the Breast—Terminology and Biology Matter: Premalignant Lesions or Preinvasive Cancer?

  2012cites this paper
• A Cohort Study of p53 Mutations and Protein Accumulation in Benign Breast Tissue and Subsequent Breast Cancer Risk

  2011cites this paper
• The Progression of Pre-invasive to Invasive Cancer

  2011cites this paper
• Ductal carcinoma in situ: Current concepts

  2010cites this paper
• Array-based multiplex analysis of DNA methylation in breast cancer tissues.

  2008cites this paper
• [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].

  2008cites this paper
• IN SITU DUKTÁLIS EMLŐKARCINÓMA KOMBINÁLT SEBÉSZI- ÉS SUGÁRKEZELÉSE: A MAGYARORSZÁGI MULTICENTRIKUS PROSPEKTÍV RANDOMIZÁLT VIZSGÁLAT

  2008cites this paper
• Immunohistochemical expression of the β‐catenin‐interacting protein B9L is associated with histological high nuclear grade and immunohistochemical ErbB2/HER‐2 expression in breast cancers

  2007cites this paper
• p53 Alterations and Protein Accumulation in Benign Breast Tissue and Breast Cancer Risk: A Cohort Study

  2006cites this paper
• Biology of Ductal Carcinoma in Situ Classification Based on Biologic Potential

  2006cites this paper
• Perfis histopatológico e imuno-histoquímico do câncer de mama: comparação entre lesões palpáveis e não-palpáveis

  2006cites this paper
• Biomolecular markers of breast cancer.

  2006cites this paper
• Expression of p53 and markers for apoptosis in breast tissue during long-term hormone therapy in cynomolgus monkeys.

  2005cites this paper
• Prognostic and Predictive Molecular Markers in DCIS: A Review

  2005cites this paper
• Mutation and overexpression of p53 as a prognostic factor in canine mammary tumors.

  2004cites this paper
• p53 expression in breast and endometrium during estrogen and tamoxifen treatment of surgically postmenopausal cynomolgus macaques

  2004cites this paper
• Analysis of p53 mutations in cells taken from paraffin-embedded tissue sections of ductal carcinoma in situ and atypical ductal hyperplasia of the breast.

  2004influential citation
• Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas.

  2003cites this paper
• Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast.

  2003cites this paper
• Correlation of p53 and cerbB2 expression and hormonal receptor status with clinicopathologic parameters in ductal carcinoma in situ of the breast.

  2002cites this paper
• Molecular and Biologic Markers of Premalignant Lesions of Human Breast

  2002cites this paper
• Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics.

  2001cites this paper
• Histopathological and cell biological factors of ductal carcinoma in situ before and after the introduction of mammographic screening.

  2001cites this paper
• Predicting the biologic behavior of ductal carcinoma in situ: an analysis of molecular markers.

  2001cites this paper
• Histological and biological evolution of human premalignant breast disease.

  2001cites this paper
• In microdissected ductal carcinoma in situ, HER‐2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology

  2000cites this paper
• p53 mutations and expression in breast carcinoma in situ.

  2000cites this paper
• Is there a role for molecular prognostic factors in the clinical management of ductal carcinoma in situ (DCIS) of the breast?

  2000cites this paper
• Biological Features of Premalignant Disease in the Human Breast

  2000cites this paper
• The hyperplasia-to-carcinoma sequence in the breast. Immunohistochemical-histologic correlations.

  2000cites this paper
• Immunohistochemical expression of p53 protein in invasive breast carcinoma: clinicopathologic correlations.

  1999cites this paper
• Management of ductal carcinoma in situ.

  1999cites this paper
• Breast preserving surgery decision making.

  1998cites this paper
• p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias.

  1998cites this paper